CompletedNot Applicable

Non-pharmaceutical Motion Sickness Mitigation

United States29 participantsStarted 2021-03-12

Plain-language summary

The purpose of this study is evaluate the effect of timing and magnitude on the administration of our nonpharmaceutical treatment to motion sickness, and to evaluate the effect of Galvanic Vestibular Stimulation (GVR) amplitude on functional fitness task performance.

Who can participate

Age range21 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Must be able to consent to participate themselves. * Must be able to attend in-person sessions at the Mayo Aerospace Medicine and Vestibular Research Laboratory in Scottsdale, AZ. * No racial ethnic groups will be excluded. * Must be fluent speakers of English. Exclusion Criteria: * History of vestibular disease, migraine, or significant balance disorder. * Traumatic brain injury. * Recent middle ear infection or recent motion sickness (within 72 hours). * History of severe motion sensitivity. * Women who are pregnant.

What they're measuring

Motion Perception

Timeframe: During the rotation of the chair, approximately 1 hr

Trial details

NCT IDNCT04859868

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-08-30

Results submitted2023-06-14

View on ClinicalTrials.gov More Healthy trials